Solid Bio aligns with FDA on late-stage trial design for Duchenne drug
Source: SeekingAlpha
2026-02-09 08:54:11 ET
More on Solid Biosciences
- Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Solid Bio rises as Duchenne study gets fully enrolled
- Seeking Alpha’s Quant Rating on Solid Biosciences
- Historical earnings data for Solid Biosciences
- Financial information for Solid Biosciences
Read the full article on Seeking Alpha
For further details see:
Solid Bio aligns with FDA on late-stage trial design for Duchenne drug
Solid Biosciences Inc.
NASDAQ: SLDB
SLDB Trading
-8.58% G/L:
$5.65 Last:
524,781 Volume:
$5.94 Open:
SLDB Latest News
February 09, 2026 08:00:00 am
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
February 06, 2026 08:00:00 am
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
SLDB Stock Data
$535,243,342
43,341,466
1.04%
23
N/A
Biotechnology & Life Sciences
Healthcare
US
Third FloorCharlestown
